Journal article
Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data
Abstract
AIM: To conduct a systematic review and meta-analysis to determine the risk of cardiovascular events and all-cause mortality associated with sulphonylureas (SUs) vs other glucose lowering drugs in patients with T2DM (T2DM).
MATERIALS AND METHODS: A systematic review of Medline, Embase, Cochrane and clinicaltrials.gov was conducted for studies comparing SUs with placebo or other antihyperglycaemic drugs in patients with T2DM. A cloglog model was …
Authors
Bain S; Druyts E; Balijepalli C; Baxter CA; Currie CJ; Das R; Donnelly R; Khunti K; Langerman H; Leigh P
Journal
Diabetes Obesity and Metabolism, Vol. 19, No. 3, pp. 329–335
Publisher
Wiley
Publication Date
3 2017
DOI
10.1111/dom.12821
ISSN
1462-8902
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Bayes TheoremCardiovascular DiseasesCause of DeathDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1HumansHypoglycemic AgentsInsulinMortalityMyocardial InfarctionProportional Hazards ModelsSodium-Glucose Transporter 2 InhibitorsStrokeSulfonylurea CompoundsSurvival RateThiazolidinediones